Terminated PHASE3 INTERVENTIONAL 1-arm NCT01950455

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Sponsor: Navidea Biopharmaceuticals

Interventions NAV5001

Updated 7 times since 2017 Last updated: Oct 4, 2018 Started: Nov 30, 2013 Primary completion: Jan 31, 2018 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The entire drug development program for this molecule was sold to another company.

Other terminated trials from Navidea Biopharmaceuticals

See all terminations from Navidea Biopharmaceuticals

Listed as NCT01950455, this PHASE3 trial focuses on Parkinson's Syndrome and remains terminated or withdrawn. Sponsored by Navidea Biopharmaceuticals, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Nov 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2018 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Navidea Biopharmaceuticals

Data source: Navidea Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orlando, United States
• Phoenix, United States